BFM
MRTX

Boothbay Fund Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Boothbay Fund Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-7,000
Closed -$1.24M – 2320
2021
Q3 		$1.24M Buy
+7,000
New +$1.13M 0.03% 662
2021
Q2 		– Sell
-108
Closed -$1.85M – 2196
2021
Q1 		$1.85M Buy
108
+56
+108% +$11.1K 0.07% 350
2020
Q4 		$1.14M Buy
+52
New +$11.2K 0.04% 449
2020
Q1 		– Sell
-168
Closed -$2.17M – 1127
2019
Q4 		$2.17M Sell
168
-244
-59% -$23.5K 0.19% 140
2019
Q3 		$3.21M Buy
412
+325
+374% +$30.5K 0.29% 79
2019
Q2 		$896K Buy
87
+24
+38% +$1.87K 0.08% 289
2019
Q1 		$462K Sell
63
-80
-56% -$5.44K 0.04% 405
2018
Q4 		$607K Buy
+143
New +$5.7K 0.09% 229
2018
Q3 		– Sell
-220
Closed -$1.08M – 977
2018
Q2 		$1.08M Buy
+220
New +$8.31K 0.09% 169

Other funds holding MRTX

S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Boothbay Fund Management's MRTX Position: Q1 2024 in Review

Boothbay Fund Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 10,000 shares — an estimated $588K sold.

Boothbay Fund Management first reported a position in MRTX in Q3 2020 and held it in 4 quarters. The position peaked at $917K in Q4 2022. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

  • Boothbay Fund Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Boothbay Fund Management sold 10,000 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $588K.
  • Boothbay Fund Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2020 and held it in 4 quarters.
  • Boothbay Fund Management's Mirati Therapeutics, Inc. Common Stock position peaked at $917K in Q4 2022.
  • 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Boothbay Fund Management's 13F filing for Q1 2024, filed 15 May 2024.